Koers Hansa Biopharma AB Nasdaq Stockholm
Aandelen
SE0002148817
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 239 mln. 21,87 mln. 20,45 mln. | Omzet 2025 * | 343 mln. 31,32 mln. 29,3 mln. | Marktkapitalisatie | 1,5 mld. 137 mln. 129 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -735 mln. -67,18 mln. -62,84 mln. | Nettowinst (verlies) 2025 * | -712 mln. -65,08 mln. -60,88 mln. | EV/omzet 2024 * | 8,27 x |
Nettoschuld 2024 * | 474 mln. 43,33 mln. 40,53 mln. | Nettoschuld 2025 * | 733 mln. 67,04 mln. 62,7 mln. | EV/omzet 2025 * | 6,53 x |
K/w-verhouding 2024 * |
-2,37
x | K/w-verhouding 2025 * |
-2,81
x | Werknemers | - |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 88,64% |
Recentste transcriptie over Hansa Biopharma AB
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 20-03-18 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/12 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 29-05-20 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 73 | 29-05-18 | |
Peter Nicklin
CHM | Chairman | 61 | 30-06-22 |
Mats Blom
BRD | Director/Board Member | 59 | 22-05-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+1,51% | 42,75 mld. | |
+49,22% | 41,61 mld. | |
+8,57% | 41,34 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |